ClinicalTrials.gg
CompletedNCT02842749Updated Feb 10, 2025Results posted

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

A Phase 4 interventional study of everolimus in Pancreatic Neuroendocrine Tumors, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2016, registered Jun 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

To evaluate safety and efficacy of everolimus (Afinitor®) in Chinese adult patients with local advanced or metastatic, well differentiated progressive pancreatic neuroendocrine tumors.

Read the detailed description

This was an open-label, multicenter, single-arm clinical study to evaluate the safety and efficacy of everolimus in Chinese adult patients with locally advanced, unresectable or metastatic, well differentiated progressive pancreatic neuroendocrine tumors. The inclusion and exclusion criteria, as well as the dosing and dose modification criteria are designed according to the approved Chinese Package Insert. The planned sample size of the study was approximately 60 subjects.

Subjects who were eligible received the treatment with everolimus provided by sponsor to treat pNET and followed the visit schedule in the protocol to collect safety and efficacy data until progression of disease, unacceptable toxicity, death, protocol deviation or other reason that may lead to discontinuation before the end of study. All subjects were followed-up for survival status every 6 months by the investigator until death, lost to follow-up, withdrawal of consent for survival or end of study.

The "End of study" is defined as either at least 75% of subjects have completed survival follow up or all subjects discontinued study treatment or the last subject finished 5-year survival follow up, whichever comes first. Final analysis was conducted at the end of the study.

02

Conditions studied

  • Pancreatic Neuroendocrine Tumors
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have histological confirmed G1 or G2 pancreatic neuroendocrine tumors(pNETs) (WHO 2010)
  • Patients must have radiological documentation of progression of disease per 1.1 within 12 months prior to enrollment.
  • per RECIST 1.1 criteria using triphasic computed tomography (CT) scan or multiphase MRI for radiologic assessment.
  • everolimus treatment which is recommended by the treating physician

Exclusion criteria

Exclusion Criteria:

  • to everolimus, to other rapamycin derivatives, or to any of the .
  • Patient who is unwilling to receive Afinitor treatment due to any reason.
  • Pregnant or nursing (lactating) women,
  • Prior therapy with mTOR inhibitors (e.g. sirolimus, temsirolimus, everolimus).
  • Use of an drug within the 30 days prior to enrollment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    everolimus (single arm)

    Participants were instructed to take everolimus at a starting dose of 10 mg orally once daily. However, dose adjustments were permitted in order to allow the participant to continue the study treatment.

    Drug: everolimus

Interventions

  • Participants were instructed to take everolimus at a starting dose of 10 mg orally once daily. However, dose adjustments were permitted in order to allow the participant to continue the study treatment.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants with treatment emergent adverse events (any AE regardless of seriousness), SAEs, AEs and SAEs on grade 3 or 4, and suspected to be related to the study drug.

    Time frame: Adverse events were reported from first dose of study treatment until end of study treatment plus follow up period of 30 days, up to a maximum duration of approximately 5 years.

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival is defined as the time from the start of study treatment to death due to any cause. OS was analyzed using the Kaplan-Meier method.

    Time frame: Up to approximately 7 years and 6 months.

  2. Progression Free Survival (PFS) by Investigator Assessment Per RECIST 1.1

    Progression free survival is defined as the time from the initiation of study treatment to disease progression or death due to any cause. PFS was analyzed using Kaplan-Meier estimates.

    Time frame: Up to approximately 2 years and 9 months

07

Results

Posted Feb 10, 2025

Participant flow

Participants took part in 5 investigative sites in China.

Participant flow — Overall Study
MilestoneEverolimus
Started61
Completed61
Not completed0

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Number of participants with treatment emergent adverse events (any AE regardless of seriousness), SAEs, AEs and SAEs on grade 3 or 4, and suspected to be related to the study drug.

Time frame:
Adverse events were reported from first dose of study treatment until end of study treatment plus follow up period of 30 days, up to a maximum duration of approximately 5 years.
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsEverolimus
AEs60
AEs-grade 3/430
AEs Suspected to be related to the study drug58
AEs Suspected to be related to the study drug-grade 3/419
SAEs17
SAEs-grade 3/411
SAEs Suspected to be related to the study drug8
SAEs Suspected to be related to the study drug-grade 3/45
SecondaryOverall Survival (OS)

Overall Survival is defined as the time from the start of study treatment to death due to any cause. OS was analyzed using the Kaplan-Meier method.

Time frame:
Up to approximately 7 years and 6 months.
Reported as:
Median · months
Overall Survival (OS)
monthsEverolimus
Overall Survival (OS)66.56 (39.66 to NA)
SecondaryProgression Free Survival (PFS) by Investigator Assessment Per RECIST 1.1

Progression free survival is defined as the time from the initiation of study treatment to disease progression or death due to any cause. PFS was analyzed using Kaplan-Meier estimates.

Time frame:
Up to approximately 2 years and 9 months
Reported as:
Median · months
Progression Free Survival (PFS) by Investigator Assessment Per RECIST 1.1
monthsEverolimus
Progression Free Survival (PFS) by Investigator Assessment Per RECIST 1.116.07 (11.04 to 21.52)

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days (on treatment period), up to a maximum duration of approximately 5 years. All cause mortality was reported until end of study, up to approximately 7 years and 6 months (on treatment plus survival follow-up period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus-on Treatment6/61 (9.8%)17/61 (27.9%)60/61 (98.4%)
Everolimus-Survival Follow-up22/55 (40%)——
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventEverolimus-on TreatmentEverolimus-Survival Follow-up
Infectious pneumonitisInfections and infestations3/61—
AstheniaGeneral disorders2/61—
Type 2 diabetes mellitusMetabolism and nutrition disorders1/61—
CachexiaMetabolism and nutrition disorders1/61—
Function liver abnormalHepatobiliary disorders1/61—
Anal abscessInfections and infestations1/61—
SepsisInfections and infestations1/61—
Herpes virus infectionInfections and infestations1/61—
Hemorrhage cerebralNervous system disorders1/61—
Hypoglycemic encephalopathyNervous system disorders1/61—
Most frequent other events
Showing 10 of 53
Most frequent other events
EventEverolimus-on TreatmentEverolimus-Survival Follow-up
AnaemiaBlood and lymphatic system disorders30/61—
Aspartate aminotransferase increasedInvestigations27/61—
Mouth ulcerationGastrointestinal disorders24/61—
StomatitisGastrointestinal disorders23/61—
DiarrhoeaGastrointestinal disorders22/61—
Alanine aminotransferase increasedInvestigations18/61—
White blood cell count decreasedInvestigations16/61—
Neutrophil count decreasedInvestigations15/61—
RashSkin and subcutaneous tissue disorders15/61—
Platelet count decreasedInvestigations14/61—

Baseline characteristics

Age, Continuous
Age, Continuous(years)Everolimus
Mean53.22 ± 14.305
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus
Female23
Male38
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Everolimus
Asian61
08

Study locations

5 sites
  • Novartis Investigative Site
    Shanghai, Shanghai Municipality 200032, China
  • Novartis Investigative Site
    Beijing, 100039, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Guangzhou, 510060, China
  • Novartis Investigative Site
    Shanghai, 200032, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Feb 2024, 95 months.

Results were first posted in Feb 2025, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2016
First posted
Jul 25, 2016
StartActual
Mar 14, 2016
Primary completionActual
Feb 22, 2024
CompletionActual
Feb 22, 2024
Results first posted
Feb 10, 2025
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02842749
Responsible party
Sponsor
First posted
Jul 25, 2016
Start date
Mar 14, 2016
Primary completion
Feb 22, 2024
Completion
Feb 22, 2024
Results posted
Feb 10, 2025
Last update
Feb 10, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion